Andrew Harper
Overview
Explore the profile of Andrew Harper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al.
Nat Med
. 2025 Feb;
PMID: 39994475
Updates of current and projected estimates of the burden are critical to monitoring the success of ongoing efforts in breast cancer control, such as the World Health Organization Global Breast...
2.
Harper A, Schulte F, Guilcher G, Truong T, Reynolds K, Spavor M, et al.
Cancers (Basel)
. 2025 Jan;
16(24.
PMID: 39766185
[...].
3.
Hughes T, Harper A, Gupta S, Frazier A, van der Graaf W, Moreno F, et al.
Lancet Oncol
. 2024 Nov;
25(12):1614-1624.
PMID: 39557059
Background: Compared with children and older adults, the burden of cancer in adolescents and young adults (ages 15-39) is understudied. We aimed to quantify the global burden of adolescent and...
4.
Harper A, Maseja N, Parkinson R, Pakseresht M, McKillop S, Henning J, et al.
JNCI Cancer Spectr
. 2023 Nov;
7(6).
PMID: 37943323
Background: Patients with cancer experience significant symptom burden. We investigated symptom severity in adolescents and young adults (18- to 39-year-olds) during the year following a cancer diagnosis and made comparisons...
5.
McGurk K, Zhang X, Theotokis P, Thomson K, Harper A, Buchan R, et al.
Am J Hum Genet
. 2023 Aug;
110(9):1482-1495.
PMID: 37652022
Understanding the penetrance of pathogenic variants identified as secondary findings (SFs) is of paramount importance with the growing availability of genetic testing. We estimated penetrance through large-scale analyses of individuals...
6.
Harper A, Schulte F, Guilcher G, Truong T, Reynolds K, Spavor M, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568747
Adverse outcomes after childhood cancer have been assessed in a range of settings, but most existing studies are historical and ascertain outcomes only after 5-year survival. Here, we describe the...
7.
Harper A, Chapel M, Hodgson G, Malinowski K, Yates I, Garle M, et al.
Vascul Pharmacol
. 2023 Jul;
152:107199.
PMID: 37500030
Background And Aims: Myeloperoxidase (MPO) and its principal reaction product hypochlorous acid (HOCl) are part of the innate immune response but are also associated with endothelial dysfunction, thought to involve...
8.
Harsanyi H, Yang L, Harper A, Jarada T, Quan M, Cheung W, et al.
Support Care Cancer
. 2023 Jun;
31(7):427.
PMID: 37369812
Purpose: Opioids are a mainstay of cancer pain management; however, patients with metastatic cancer are often excluded from studies, leading to a lack of evidence on whether increased prescribing (dosage...
9.
Prieur A, Harper A, Khan M, Vire B, Joubert D, Payen L, et al.
BMC Cancer
. 2023 Apr;
23(1):305.
PMID: 37016331
Background: Recurrence and metastases are still frequent outcomes after initial tumour control in women diagnosed with breast cancer. Although therapies are selected based on tumour characteristics measured at baseline, prognostic...
10.
Yang L, Harper A, Imm K, Grubb 3rd R, Kim E, Colditz G, et al.
Urology
. 2023 Feb;
175:137-143.
PMID: 36841358
Objective: To prospectively examine the influence of weight status on urinary and sexual function in clinically localized prostate cancer patients treated by radical prostatectomy (RP). Methods: The Prostatectomy, Incontinence and...